The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
Douglas S. Corwin, Peter T. Ender, Nitasa Sahu, Ryan A Durgham, Dennis M McGorry, A.K. Rahman, Jill Stoltzfus, Jeffrey A. Jahre
Abstract
Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.
Topics & Concepts
MedicineEmergency departmentCoronavirus disease 2019 (COVID-19)Emergency medicineAmbulatorySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respiratory illness2019-20 coronavirus outbreakMedical emergencyIntensive care medicineDiseasePediatricsInternal medicineRespiratory systemOutbreakVirologyInfectious disease (medical specialty)PsychiatryCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19